Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma.

TL;DR: The recurrence of HLH with a high Epstein-Barr virus load but without relapse of HD in the patient suggests that Epstein- Barr virus may have a major pathogenetic role in the specific disorder HLH-HD.

TL;DR: Study findings do not support a strong role for nutrients and genetic variation in the one-carbon metabolism pathway in susceptibility to Hodgkin lymphoma, and associations between diet and risk of Epstein-Barr virus-negative disease require confirmation in other populations.

TL;DR: Nanatinostat and valganciclovir are effective in treating recurrent EBV-positive lymphoid malignancies.

TL;DR: It is demonstrated that methyl CpG binding magnetic beads can be used to fractionate among sources of EBV DNA (DNA extracted from laboratory-purified virions vs DNA extracted from latently infected cell lines), and showed that this technique can distinguish EBVDNA from patients with EBV-associated tumors and viral DNA from patients withoutEBV- associated tumors.

TL;DR: It is suggested that age, sex, ethnicity and the physiologic effects of poverty may represent biologic modifiers of the EBV association and confirmed that this association is strongly but variably linked to histologic subtype.

TL;DR: The development of Hodgkin's disease may in some patients be preceded by enhanced activation of Epstein-Barr virus, and associations were stronger in serum samples obtained at least three years before diagnosis than in serum sample obtained closer to diagnosis.

TL;DR: Recent studies suggest a role for EBV viral load testing in nasopharyngeal carcinoma, Hodgkin's disease, and AIDS patients with brain lymphoma and further research is needed to define more fully the clinical utility of viral load tests in the full spectrum of EBV-associated diseases.